The global artificial coma/medically induced coma market was valued at $640.17 million in 2020, and is projected to reach $868.63 million by 2030, registering a CAGR of 3.1%.
Artificial coma/medically induced coma is a state of unconsciousness. During this condition, a person does not respond to environment. The person is alive and looks like he/she is sleeping. An artificial coma effectively shuts down the patient’s brain activity. It is a deep, but reversible unconsciousness which doctors purposely induce. The main aim of medically induced coma is to reach at the level of sedation, which is called ‘burst suppression’. The brain is completely quite in that state for some time. Doctors use tactic for the treatment of those who suffered from a serious traumatic brain injury. Before undergoing the surgical procedure, doctors give certain medications to patient for the management of pain.
There are couple of options to inducing coma for medical reasons such as during surgical procedure of stroke, status epilepticus and other brain infections. High pressure on brain caused swelling and it stops the flow of oxygen to the brain leads the damage of the brain tissue. Reducing the electrical activity of the brain and induced coma can reduce the swelling and inflammation of the brain. The global artificial coma/medically induced coma market is majorly driven by an alarming increase in the prevalence of traumatic brain injury, rise in cases of stroke, and advancement in R&D activities for drug development. According to Centers for Disease Control and Prevention, there were an approximately 61,000 traumatic brain injury cases in the U.S. in 2019. Traumatic brain injury is mostly caused by vehicle accidents, or accidental falls. These factors increase the number of traumatic brain injury surgeries. Moreover, in March 2021, B. Braun received Food and Drug Administration approval for the use of Propofol-Lipuro injectable emulsion to maintain anesthesia in patients who require mechanical ventilation intensive care unit during the COVID-19 pandemic.
It provides protection to brain and ultimately reduces the pain of swelling. Thus, increase in use of anesthetics drugs to induce coma in patients who are undergoing various types of surgeries are expected to propel the growth of the market.
Increase in the number of surgical procedures such as cosmetic surgery, brain surgery leads to surge in usage of drugs such as propofol and barbiturate to induce coma in patients are the major factors that drive the global artificial coma/medically induced coma market. Moreover, increase in prevalence of geriatric population significantly contributes toward the market growth. Rise in production of various types of drugs to induce coma acts a key driving force of the global market. Moreover, in June 2019, Fresenius Kabi announced the immediate availability of dexmedetomidine hydrochloride in 0.9% sodium chloride injection, a medication used to induce coma during surgery and other procedures. For instance, in 2020, Medova and the New York School of Regional Anesthesia entered a partnership to introduce Safira injection in the U.S for anesthetic use.
In addition, as per the statistics provided by the American Society of Plastic Surgeons in 2019, approximately 1.8 million cases of cosmetic minimally-invasive surgeries were performed in the U.S. The rise in demand for various anesthetic for surgical procedures being performed. The application of anesthetics in general surgeries is expected to drive the growth of the market. Furthermore, the data provided by Organization for Economic Co-operation and Development, in Germany, total number of 45,307 cases of coronary artery bypass grafting procedures were performed in 2018. Hence, the increasing incidences of emergency surgeries, extensive uses of propofol and barbiturate drugs propels the growth of the market.
Surgery is known as the best cure for various serious types of diseases. The prevalence of cardiovascular diseases in China has been increasing continuously. As per the report published in the Journal of Geriatric Cardiology by Li-Yuan Ma, approximately 290 million patients of cardiovascular disorders in China and approximately 2 in 5 deaths were happened in China due to CVD. Therefore, the rising number of cardiovascular diseases results in increasing number of surgeries that help to boost the growth of the market. Ageing population is at high risk of having cardiovascular diseases, which leads to increasing demand for surgical interventions. Thus, increasing geriatric population is also expected to drive the substantial growth of the market during forecast period.
On the contrary, side effects associated with artificial coma/medically induced coma and risk associated with pregnant women are anticipated to hinder the market growth during the forecast period. Emerging markets & significant R&D to develop efficient drugs, and unmet demand in the under developed & developing countries are projected to provide substantial growth opportunities for key players in artificial coma/medically induced coma market.
The global artificial coma/medically induced coma market is segmented on the basis of drug type, application, distribution channel, and region. By drug type, the market is categorized into propofol and barbiturate. By application, the market is fragmented into status epilepticus, stroke, traumatic brain injury, brain infections, drug overdose, and others. By distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies and online providers. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global artificial coma/medically induced coma market are Astrazeneca Plc., B. Braun Melsungen, Baxter Healthcare Corporation, Dr. Reddy's Laboratories, Fresenius SE & CO., Hikma Pharmaceuticals, Pfizer Inc., Piramal Healthcare, Teva Pharmaceuticals Industries Ltd., and Viatris Inc.
Artificial coma/medically induced coma is a state of unconsciousness. During this condition, a person does not respond to environment. The person is alive and looks like he/she is sleeping. An artificial coma effectively shuts down the patient’s brain activity. It is a deep, but reversible unconsciousness which doctors purposely induce. The main aim of medically induced coma is to reach at the level of sedation, which is called ‘burst suppression’. The brain is completely quite in that state for some time. Doctors use tactic for the treatment of those who suffered from a serious traumatic brain injury. Before undergoing the surgical procedure, doctors give certain medications to patient for the management of pain.
There are couple of options to inducing coma for medical reasons such as during surgical procedure of stroke, status epilepticus and other brain infections. High pressure on brain caused swelling and it stops the flow of oxygen to the brain leads the damage of the brain tissue. Reducing the electrical activity of the brain and induced coma can reduce the swelling and inflammation of the brain. The global artificial coma/medically induced coma market is majorly driven by an alarming increase in the prevalence of traumatic brain injury, rise in cases of stroke, and advancement in R&D activities for drug development. According to Centers for Disease Control and Prevention, there were an approximately 61,000 traumatic brain injury cases in the U.S. in 2019. Traumatic brain injury is mostly caused by vehicle accidents, or accidental falls. These factors increase the number of traumatic brain injury surgeries. Moreover, in March 2021, B. Braun received Food and Drug Administration approval for the use of Propofol-Lipuro injectable emulsion to maintain anesthesia in patients who require mechanical ventilation intensive care unit during the COVID-19 pandemic.
It provides protection to brain and ultimately reduces the pain of swelling. Thus, increase in use of anesthetics drugs to induce coma in patients who are undergoing various types of surgeries are expected to propel the growth of the market.
Increase in the number of surgical procedures such as cosmetic surgery, brain surgery leads to surge in usage of drugs such as propofol and barbiturate to induce coma in patients are the major factors that drive the global artificial coma/medically induced coma market. Moreover, increase in prevalence of geriatric population significantly contributes toward the market growth. Rise in production of various types of drugs to induce coma acts a key driving force of the global market. Moreover, in June 2019, Fresenius Kabi announced the immediate availability of dexmedetomidine hydrochloride in 0.9% sodium chloride injection, a medication used to induce coma during surgery and other procedures. For instance, in 2020, Medova and the New York School of Regional Anesthesia entered a partnership to introduce Safira injection in the U.S for anesthetic use.
In addition, as per the statistics provided by the American Society of Plastic Surgeons in 2019, approximately 1.8 million cases of cosmetic minimally-invasive surgeries were performed in the U.S. The rise in demand for various anesthetic for surgical procedures being performed. The application of anesthetics in general surgeries is expected to drive the growth of the market. Furthermore, the data provided by Organization for Economic Co-operation and Development, in Germany, total number of 45,307 cases of coronary artery bypass grafting procedures were performed in 2018. Hence, the increasing incidences of emergency surgeries, extensive uses of propofol and barbiturate drugs propels the growth of the market.
Surgery is known as the best cure for various serious types of diseases. The prevalence of cardiovascular diseases in China has been increasing continuously. As per the report published in the Journal of Geriatric Cardiology by Li-Yuan Ma, approximately 290 million patients of cardiovascular disorders in China and approximately 2 in 5 deaths were happened in China due to CVD. Therefore, the rising number of cardiovascular diseases results in increasing number of surgeries that help to boost the growth of the market. Ageing population is at high risk of having cardiovascular diseases, which leads to increasing demand for surgical interventions. Thus, increasing geriatric population is also expected to drive the substantial growth of the market during forecast period.
On the contrary, side effects associated with artificial coma/medically induced coma and risk associated with pregnant women are anticipated to hinder the market growth during the forecast period. Emerging markets & significant R&D to develop efficient drugs, and unmet demand in the under developed & developing countries are projected to provide substantial growth opportunities for key players in artificial coma/medically induced coma market.
The global artificial coma/medically induced coma market is segmented on the basis of drug type, application, distribution channel, and region. By drug type, the market is categorized into propofol and barbiturate. By application, the market is fragmented into status epilepticus, stroke, traumatic brain injury, brain infections, drug overdose, and others. By distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies and online providers. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global artificial coma/medically induced coma market are Astrazeneca Plc., B. Braun Melsungen, Baxter Healthcare Corporation, Dr. Reddy's Laboratories, Fresenius SE & CO., Hikma Pharmaceuticals, Pfizer Inc., Piramal Healthcare, Teva Pharmaceuticals Industries Ltd., and Viatris Inc.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides an extensive analysis of the current and emerging market trends and dynamics in the global artificial coma/medically induced coma market to identify the prevailing opportunities.
- This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
- Comprehensive analysis of factors that drive and restrict the market growth is provided.
- Region- & country-wise analysis is provided to understand the market trends and dynamics.
KEY MARKET SEGMENTS
By Drug Type
- Propofol
- Barbiturate
By Application
- Status Epilepticus
- Stroke
- Traumatic Brain Injury
- Brain Infections
- Drug Overdose
- Others
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
KEY MARKET PLAYERS
- Astrazeneca Plc.
- B. Braun Melsungen
- Baxter Healthcare Corporation
- Dr.Reddy's Laboratories
- Fresenious SE & CO.
- Hikma Pharmaceuticals
- Pfizer Inc.
- Piramal Healthcare
- Teva Pharmaceuticals Industries Ltd.
- Viatris Inc
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET LANDSCAPE
CHAPTER 4: ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE
CHAPTER 5: ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY APPLICATION
CHAPTER 6: ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY REGION
CHAPTER 8: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Astrazeneca Plc.
- B. Braun Melsungen
- Baxter Healthcare Corporation
- Dr.Reddy's Laboratories
- Fresenious SE& CO.
- Hikma Pharmaceuticals
- Pfizer Inc.
- Piramal Healthcare
- Teva Pharmaceuticals Industries Ltd.
- Viatris Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 241 |
| Published | December 2021 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 640.17 million |
| Forecasted Market Value ( USD | $ 868.63 million |
| Compound Annual Growth Rate | 3.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
